Patents Examined by Cecilia M. Jaisle
  • Fused bicycloheterocycle substituted azabicyclic alkane derivatives
    Patent number: 7872017
    Abstract: The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: January 18, 2011
    Assignee: Abbott Laboratories
    Inventors: Jianguo Ji, Tao Li, Christopher L. Lynch, Murali Gopalakrishnan
  • Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors
    Patent number: 7872010
    Abstract: Provided herein are compositions of a class of substituted diazabicycloalkane derivative compounds, which are useful as modulators of nicotinic acetylcholine receptors. The compounds are useful in treating conditions and disorders prevented by, or ameliorated by, nicotinic acetylcholine receptors.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: January 18, 2011
    Assignee: Abbott Laboratories
    Inventors: Jennifer M. Frost, Jianguo Ji, Tao Li, Diana L. Nersesian, Karin R. Tietje
  • Cytokine inhibitors
    Patent number: 7868001
    Abstract: A compound of Formula I: Each variable is defined in the specification. This invention relates to a method of decreasing a level of a cytokine (e.g., TNF? or interlukine such as IL-1?) in a subject with a compound of Formula I. It also relates to a method of treating a disorder mediated by an overproduction of a cytokine with such a compound.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: January 11, 2011
    Assignee: Hutchison Medipharma Enterprises Limited
    Inventors: Wei Deng, Wei-Guo Su, Yu Cai, Jeff Duan
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 7868018
    Abstract: The invention provides compounds of Formula I: wherein R1-R6 are described in the Summary of the Invention; the pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, b-RAF, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKK?, IKK?, JNK2?2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFR?, PKA, PKB?, PKD2, Rsk1, SAPK2?, SAPK2?, SAPK3, SGK, Tie2 and TrkB kinases.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: January 11, 2011
    Assignee: IRM LLC
    Inventors: Yongping Xie, Guobao Zhang, Xing Wang, Nathanael S. Gray, Yi Liu
  • Isethionate salt of a selective CDK4 inhibitor
    Patent number: 7863278
    Abstract: Disclosed are polymorphs of the isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: January 4, 2011
    Assignee: Warner-Lambert CompanyLLC
    Inventors: Vladimir Genukh Beylin, Anthony Clyde Blackburn, David Thomas Erdman, Peter Laurence Toogood
  • Fused cyclic systems useful as inhibitors of TEC family protein kinases
    Patent number: 7855214
    Abstract: The present invention relates to compounds useful as inhibitors of Tec family protein kinases. These compounds have the general formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, G, Cy1, and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: January 26, 2005
    Date of Patent: December 21, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Juan-Miguel Jimenez, Sanjay Patel, David Kay, Ronald Knegtel, Oliver Philps
  • Aza-indolyl compounds and methods of use
    Patent number: 7855216
    Abstract: The invention relates to azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: December 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Karen Williams, Stephen Price, Hazel Joan Dyke, John Gary Montana, Mark S. Stanley, Liang Bao, Wendy Lee
  • Triazolophthalazines
    Patent number: 7851472
    Abstract: The compounds of formula I in which R1 and R2 have the meanings as given in the description are novel effective PDE2 inhibitors.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: December 14, 2010
    Assignee: NYCOMED GmbH
    Inventors: Beate Schmidt, Steffen Weinbrenner, Dieter Flockerzi, Raimund Kuelzer, Hermann Tenor, Hans-Peter Kley
  • N,N?-diphenylurea derivatives suitable as kinase inhibitors
    Patent number: 7846927
    Abstract: Compounds of the formula (I), in which R1, R3 and X have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: December 7, 2010
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Alfred Jonczyk, Wilfried Rautenberg
  • Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
    Patent number: 7842698
    Abstract: The present invention relates to pyridine methylene azolidinone compounds of Formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, allergy, asthma, pancreatitis, multi-organ failure, kidney diseases, platelet aggregation, cancer, sperm motility, graft rejection or lung injuries. Specifically, the present invention is related to pyridine methylene azolidinone derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide-3-kinases, PI3Ks.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: November 30, 2010
    Assignee: Merck Serono S.A.
    Inventors: Thomas Rueckle, Anna Quattropani, Vincent Pomel, Jerome Dorbais, David Covini, Alexander Bischoff
  • Methods of preparing quinolone analogs
    Patent number: 7834180
    Abstract: Compounds having formula 1: are produced by contacting a compound having formula (6A) with a compound having formula (7), or tautomers thereof, in the presence of a non-nucleophilic base, wherein V, A, Z, L, L1, W, X, B?, R and n are as defined herein.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: November 16, 2010
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Peter C. Chua, Johnny Y. Nagasawa, Michael Schwaebe, Fabrice Pierre
  • 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
    Patent number: 7829560
    Abstract: 1,4 disubstituted napthylenes, of formula (I), are disclosed. These compounds may be useful in treating cell-proliferative diseases.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: November 9, 2010
    Assignee: Arqule, Inc.
    Inventors: Mark A. Ashwell, Yanbin Liu, Syed Ali, Jason Hill, Woj Wrona
  • Pyrido[4,3-]pyrimidin-4(3)-one derivatives as calcium receptor antagonists
    Patent number: 7829572
    Abstract: The present invention is directed to novel pyrido[4,3-d]pyrimidin-4(3H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variables R1, R2, R3, R4 and R5 are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: November 9, 2010
    Assignee: Pfizer Inc
    Inventors: Mary T. Didiuk, Kevin K. Liu, David A. Griffith, Angel Guzman-Perez, Feng C. Bi, Daniel P. Walker
  • Dipeptidyl peptidase inhibitors
    Patent number: 7825242
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound of the formula: wherein R2 is amino (C1-6)alkyl, hetero(C3-12)cycloakyl, hetero(C4-12)bicycloaryl, heteroaryl, or cyano; and W, X, Y, Z, R1, R5 and R7 are as defined herein.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: November 2, 2010
    Assignee: Takeda Pharmaceutical Company Limted
    Inventors: Jun Feng, Stephen L. Gwaltney, Betty Lam, Zhiyuan Zhang
  • 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
    Patent number: 7820669
    Abstract: The compounds of a certain formula (1), in which R1, R2, R3 and R9 have the meanings as given in the description, are novel effective PDE4 inhibitors.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: October 26, 2010
    Assignee: NYCOMED GmbH
    Inventors: Wiro M. P. B. Menge, Geert Jan Sterk
  • Process for the synthesis of CMHTP and intermediates thereof
    Patent number: 7820816
    Abstract: The present invention provides 3-benzyloxy-2-aminopyridine (BOPA), 3-(2-Hydroxyethyl)-2-methyl-9-hydoxy-4H-pyrido[1,2-a]pyrimidine-4-one (HMBP), 3-(2-Chloroethyl)-2-methyl-9-hydoxy-4H-pyrido[1,2-a]pyrimidine-4-one (CMHP) and 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]-pyrimidin-4-one (CMHTP) useful as intermediates for the preparation of paliperidone. The present invention also provides processes for preparing these intermediates and for preparing paliperidone.
    Type: Grant
    Filed: August 23, 2007
    Date of Patent: October 26, 2010
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Ben-Zion Dolitzky, Evgeny Shapiro, Santiago Ini, Yaron Shmuely, Eli Lancry
  • 2-substituted pyrimidines and their use as pesticides
    Patent number: 7820647
    Abstract: The invention relates to 2-substituted pyrimidines of the formula I in which the index n and the substituents L and R1 to R3 are as defined in the description and X is a group —CH—Ra, —N—Rb—, —O— or —S—; Ra may be hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, cyano or C1-C6-alkoxycarbonyl; Rb is hydrogen, C1-C6-alkyl or C3-C6-cycloalkyl; T is a group —CH—Ra—; p is an integer from 1 to 4; Y is a group —CH—Ra— or —N—Rb—, o is 0 or 1; Z is O, S or a group N(Rc) Rc is hydrogen, C1-C6-alkyl or C1-C6-alkoxy, and to processes for their preparation, to pesticidal compositions comprising them and to their use as pesticides.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: October 26, 2010
    Assignee: BASF Aktiengesellschaft
    Inventors: Anja Schwögler, Frank Schieweck, Joachim Rheinheimer, Markus Gewehr, Bernd Müller, Thomas Grote, Wassilios Grammenos, Udo Hünger, Carsten Blettner, Peter Schäfer, Oliver Wagner, Reinhard Stierl, Ulrich Schöfl, Siegfried Strathmann, Maria Scherer
  • P70S6 kinase modulators and method of use
    Patent number: 7816353
    Abstract: Compounds of formula III: wherein R5a, R3, X, Y, Q, R1a and R1b are as defined in the specification, pharmaceutically acceptable salts thereof, and methods of use thereof.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: October 19, 2010
    Assignee: Exelixis, Inc.
    Inventors: Wei Cheng, Erick Wang Co, Moon Hwan Kim, Rhett Ronald Klein, Donna T. Le, Amy Lew Tsuhako, John M. Nuss, Wei Xu
  • Methods of preparing quinolone analogs
    Patent number: 7816524
    Abstract: Compounds having formula 1 are produced by contacting a compound having formula(6A) with a compound having formula (7), or tautomers thereof, in the presence of a non-nucleophilic base, wherein V, A, Z, L, L1,W, X, B?, R and N are as defined herein.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: October 19, 2010
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Peter C. Chua, Johnny Y. Nagasawa, Michael Schwaebe, Fabrice Pierre
  • Azabicyclic heterocycles as cannabinoid receptor modulators
    Patent number: 7816357
    Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R4, R5, m and n are described herein.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: October 19, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guixue Yu, William R. Ewing, Amarendra B. Mikkilineni, Annapurna Pendri, Bruce A. Ellsworth, Philip M. Sher, Samuel Gerritz, Chongqing Sun, Natesan Murugesan, Ximao Wu